Angina Differential Diagnosis: A Comprehensive Guide for Clinicians

Angina, a cardinal symptom of ischemic heart disease, remains a significant global health concern due to its association with high morbidity and mortality rates. In the United States alone, approximately 9 million individuals experience angina, highlighting the clinical challenge in its diagnosis and management. This article aims to provide an in-depth exploration of angina, with a particular focus on its differential diagnosis, equipping healthcare professionals with the knowledge to accurately evaluate and manage this complex condition.

Understanding Angina and Its Diverse Origins

Chest pain, the hallmark of angina, is a symptom with a broad spectrum of potential etiologies, ranging from benign non-cardiac conditions to life-threatening cardiac emergencies. A meticulous approach to patient evaluation, incorporating detailed history and thorough physical examination, is paramount to effectively differentiate between cardiac and non-cardiac causes of chest pain, especially in the context of suspected acute coronary syndrome (ACS). Angina itself is a key indicator of ACS and is further classified into stable and unstable forms. Stable angina typically manifests predictably with exertion, while unstable angina, characterized by symptoms at rest or with minimal exertion, necessitates urgent medical attention and intervention. Prompt recognition of angina symptoms is crucial for optimizing patient outcomes and preventing adverse cardiac events.

Etiological Spectrum of Chest Pain: Cardiac and Non-Cardiac Causes

The origins of chest pain are diverse, encompassing non-cardiac, non-ischemic cardiac, and ischemic cardiac etiologies. Non-cardiac causes are prevalent and include conditions such as gastroesophageal reflux disease (GERD), pulmonary disorders, musculoskeletal issues, and psychological conditions like anxiety and panic attacks. Non-ischemic cardiac causes, such as pericarditis, also present with chest pain but do not involve myocardial ischemia. However, the most clinically significant cause of chest pain in the context of angina is cardiac ischemia, primarily resulting from atherosclerosis of the coronary arteries and coronary vasospasm.

Ischemic angina arises from an imbalance between myocardial oxygen supply and demand. In stable angina, this mismatch is typically triggered by increased oxygen demand during physical exertion. In contrast, unstable angina can occur even at rest, reflecting a more critical reduction in coronary blood flow. Increased myocardial oxygen demand during exercise is primarily driven by factors such as increased heart rate, elevated blood pressure, and enhanced myocardial contractility. In healthy individuals, coronary arteries respond to increased oxygen demand with vasodilation, ensuring adequate blood flow. However, in the presence of coronary artery atherosclerosis, this vasodilatory response is impaired, leading to myocardial ischemia and the characteristic chest pain of angina.

Vasospastic angina, also known as variant angina or Prinzmetal angina, shares the characteristic of occurring at rest with unstable angina but is distinct in its pathophysiology. Unlike stable and unstable angina, vasospastic angina is not directly related to coronary atherosclerosis but rather to transient spasms of the coronary arteries.

Epidemiology of Angina: Prevalence and Risk Factors

Chronic stable angina is a common condition, affecting an estimated 30,000 to 40,000 individuals per million in Western countries. The prevalence of angina increases with age in both sexes. For individuals aged 45 to 64, the prevalence ranges from 4% to 7% in men and 5% to 7% in women. In older age groups (65 to 84 years), prevalence rises significantly to 14% to 15% in men and 10% to 12% in women.

Several modifiable risk factors contribute to the development of angina, including hyperlipidemia, hypertension, current or past tobacco use, diabetes mellitus, and obesity/metabolic syndrome. Elevated body mass index (BMI) has been identified as an independent risk factor for coronary artery disease (CAD). Non-modifiable risk factors include advancing age, male gender, a family history of CAD, and certain ethnic origins.

Pathophysiology of Anginal Pain: Cellular Mechanisms

The heart muscle relies on a continuous and adequate supply of oxygen for energy production, essential for its contractile function. At the cellular level, myocardial ischemia triggers anaerobic glycolysis, an inefficient energy-producing pathway. This metabolic shift leads to an accumulation of hydrogen ions, potassium ions, and lactate in the venous blood draining the ischemic myocardial region. The increased concentration of hydrogen ions interferes with calcium ion interaction within myocardial cells, resulting in impaired contractility, manifesting as hypokinesia or akinesia in the affected area. In stable angina, these changes in oxygen supply are typically provoked by triggers that increase myocardial oxygen demand, such as physical exertion, emotional stress, or exposure to cold temperatures.

Clinical Presentation: History and Physical Examination in Angina

Patients experiencing ACS commonly present with angina, which they often describe as chest pain, pressure, tightness, or heaviness. This discomfort may radiate to the jaw, left arm, or back. Angina can be accompanied by shortness of breath (dyspnea), excessive sweating (diaphoresis), nausea, or a combination of these symptoms. In stable angina, chest pain is characteristically precipitated by physical exertion and relieved by rest and/or nitroglycerin. Conversely, in unstable angina or myocardial infarction (MI), including non-ST segment elevation MI (NSTEMI) and ST-segment elevation MI (STEMI), chest pain may not fully resolve with rest or nitroglycerin. Stable angina symptoms typically last for about 5 minutes before subsiding with rest or nitroglycerin administration. However, it is important to recognize that classic angina symptoms may be absent or atypical, particularly in certain populations such as individuals with diabetes. Therefore, a high index of suspicion for angina is crucial in patients with significant cardiac risk factors, even if their presentation deviates from the classic description.

Physical examination findings in patients with angina may be unremarkable, particularly between episodes of pain. However, during an episode, patients may appear uncomfortable, anxious, diaphoretic, and may be clutching their chest. Vital signs may be within normal limits or reveal tachycardia (rapid heart rate) and tachypnea (rapid breathing) as compensatory responses to myocardial ischemia and pain.

Diagnostic Evaluation of Angina

In patients presenting with suspected angina, the utility of cardiac testing is guided by the patient’s pretest probability of ACS. Pretest probability assessment involves considering the patient’s clinical presentation, including the characteristics of their chest pain, in conjunction with their cardiovascular risk factors. In individuals with very high or very low pretest probability, the incremental value of diagnostic tests may be limited, as they are less likely to alter clinical management.

Initial diagnostic evaluation typically includes a 12-lead electrocardiogram (ECG), chest X-ray, and basic laboratory tests, including a complete blood count (CBC), basic metabolic panel (BMP), and serial troponin levels if ACS is suspected. In cases of stable angina, unstable angina, or NSTEMI, the initial ECG may not show any acute abnormalities. ECG findings indicative of myocardial ischemia include T-wave flattening or inversions, and ST-segment depressions. Further diagnostic testing may include exercise or pharmacological stress testing, with or without nuclear perfusion imaging, and invasive diagnostic coronary angiography (heart catheterization). In STEMI, characteristic ECG changes, such as ST-segment elevation, are typically present and necessitate immediate coronary revascularization to restore blood flow to the ischemic myocardium.

Therapeutic Management of Angina: Goals and Strategies

The management of chronic stable angina is directed towards two primary goals: alleviating anginal symptoms and slowing the progression of underlying coronary artery disease to prevent future cardiac events. Effective management is multifaceted, incorporating lifestyle modifications, risk factor management, and pharmacological therapy as essential components. In cases where symptoms remain refractory to medical therapy, coronary revascularization procedures may be considered. However, while revascularization can effectively control anginal symptoms, clinical trials have not demonstrated a reduction in major cardiovascular events compared to optimal medical therapy alone in stable angina.

Lifestyle modifications are foundational in angina management and include regular physical exercise, weight management, and smoking cessation. Patients should be strongly encouraged to adopt these healthy lifestyle practices. Risk factor modification focuses on controlling hypertension, hyperlipidemia, and diabetes mellitus. Medications commonly used for risk factor modification and to prevent disease progression include aspirin, statins, angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs).

Pharmacological therapy plays a crucial role in both symptom control and mitigating the risk of atherosclerosis progression and subsequent cardiac events. Antianginal medications can be classified based on their mechanisms of action in relieving angina. The primary goal of symptomatic treatment is to reduce myocardial oxygen consumption.

Since heart rate is a major determinant of myocardial oxygen consumption, many anginal episodes are triggered by an increase in heart rate. Three classes of drugs commonly used to treat angina reduce symptoms by decreasing heart rate: beta-blockers, ivabradine, and non-dihydropyridine calcium channel blockers (e.g., verapamil, diltiazem). Calcium channel blockers should be used cautiously or avoided in patients with left ventricular dysfunction and reduced ejection fraction due to their potential negative inotropic effects.

Another mechanism for angina symptom relief is through vascular smooth muscle relaxation, leading to coronary artery vasodilation and improved myocardial perfusion. Medications that act via this mechanism include dihydropyridine calcium channel blockers (e.g., amlodipine, nifedipine), nitrates, and nicorandil.

Ranolazine is another antianginal medication used in chronic stable angina. It works by inhibiting the late sodium current in ventricular myocardial cells, which reduces diastolic contractile dysfunction and improves myocardial efficiency.

The treatment of unstable angina focuses on immediate pain relief, limiting myocardial damage, and reducing the risk of adverse outcomes, including morbidity and mortality.

Nitrates, such as nitroglycerin, are used for rapid chest pain relief in unstable angina. While they do not have a mortality benefit, they cause vasodilation, reducing preload and left ventricular end-diastolic volume, thereby decreasing myocardial oxygen consumption. Nitrates are contraindicated in patients with hypotension and those who have used phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil) within the preceding 48 hours due to the risk of severe hypotension.

Morphine may be used for pain relief in unstable angina when nitrates alone are insufficient. Morphine provides analgesia and also has some vasodilatory properties. However, it does not have a mortality benefit and should be used judiciously.

Beta-blockers are crucial in the management of unstable angina and have been shown to reduce mortality. They decrease heart rate, contractility, and blood pressure, all of which contribute to reduced myocardial oxygen demand.

Antiplatelet agents, specifically dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor (clopidogrel, ticagrelor, or prasugrel), are essential to reduce the risk of cardiovascular events in patients with ACS, including unstable angina and myocardial infarction. DAPT significantly decreases the risk of acute myocardial infarction, cardiovascular death, and stroke.

Anticoagulants are also used in unstable angina to reduce mortality by preventing thrombus propagation and re-infarction. They are typically administered intravenously in the acute setting, in conjunction with antiplatelet agents.

Anatomic assessment of coronary arteries and consideration of revascularization are critical components of unstable angina management. High-risk patients, identified through risk stratification tools, should be considered for urgent coronary angiography and revascularization (percutaneous coronary intervention or coronary artery bypass grafting) to restore coronary blood flow and prevent further myocardial damage.

Angina Differential Diagnosis: A Systematic Approach

The differential diagnosis of angina is broad and necessitates a systematic approach to effectively distinguish cardiac angina from other conditions that can mimic its symptoms. The differential can be categorized by organ systems:

1. Gastrointestinal Disorders:

• Gastroesophageal Reflux Disease (GERD): Heartburn, acid regurgitation, and chest pain are common GERD symptoms. Pain is often burning, located in the epigastric or substernal area, and may be exacerbated by meals or lying down. Unlike angina, GERD pain is typically not related to exertion and may be relieved by antacids.
• Hiatal Hernia: This condition, where part of the stomach protrudes into the chest cavity, can cause chest pain that may resemble angina. Symptoms can include heartburn, regurgitation, and dysphagia. Pain may be positional or related to meals.
• Peptic Ulcer Disease: Gastric or duodenal ulcers can cause epigastric pain that may radiate to the chest. Pain is often described as gnawing or burning and may be related to meals (worsened by meals in gastric ulcers, relieved by meals in duodenal ulcers).
• Esophageal Spasm: Spasms of the esophageal muscles can cause intense chest pain that can be indistinguishable from angina. Pain is often described as squeezing or crushing and may be accompanied by dysphagia. It is not typically related to exertion.
• Gallbladder Disease (Biliary Colic): Pain from gallstones or gallbladder inflammation can sometimes radiate to the chest, mimicking angina. Pain is usually located in the right upper quadrant or epigastrium and may be triggered by fatty meals.

2. Pulmonary Conditions:

• Pneumothorax: A collapsed lung can cause sudden, sharp chest pain, often accompanied by shortness of breath and decreased breath sounds on the affected side. Pain is typically pleuritic (worsened by breathing).
• Pneumonia and Pleurisy: Infections of the lung or pleura (lining of the lungs) can cause chest pain, cough, fever, and shortness of breath. Pleuritic pain is characteristic, worsening with deep breaths or coughing.
• Pulmonary Embolism (PE): A blood clot in the lungs can cause sudden chest pain, shortness of breath, rapid heart rate, and cough. PE can be life-threatening and should be considered in patients with risk factors for venous thromboembolism.
• Asthma and COPD Exacerbation: Severe asthma or chronic obstructive pulmonary disease (COPD) exacerbations can cause chest tightness and shortness of breath, which may be mistaken for angina. Wheezing and cough are usually prominent features.

3. Musculoskeletal Disorders:

• Costochondritis: Inflammation of the cartilage that connects the ribs to the breastbone (costochondral joints) can cause localized chest wall pain that is often sharp and reproducible with palpation. Pain is typically worsened by movement or pressure on the chest.
• Rib Injury or Fracture: Trauma to the chest wall can result in rib fractures or injuries, causing localized pain that is exacerbated by breathing or movement.
• Muscle Strain or Spasm: Strain or spasm of the chest wall muscles can cause localized pain that is worsened by movement or palpation.
• Fibromyalgia: This chronic pain syndrome can cause widespread musculoskeletal pain, including chest wall pain, which may be confused with angina. Other symptoms include fatigue, sleep disturbances, and tender points.

4. Psychiatric Conditions:

• Panic Attack: Panic attacks can manifest with chest pain, shortness of breath, palpitations, dizziness, and fear of death. Symptoms are typically sudden in onset and accompanied by significant anxiety. Unlike angina, panic attack symptoms are not related to exertion and are often associated with psychological triggers.
• Generalized Anxiety Disorder: Chronic anxiety can manifest with various physical symptoms, including chest tightness or discomfort. Symptoms are usually less intense than angina and are associated with persistent worry and anxiety.

5. Cardiac Non-Ischemic Conditions:

• Pericarditis: Inflammation of the pericardium (sac surrounding the heart) causes sharp, stabbing chest pain that is typically pleuritic and positional (worsened by lying down, relieved by sitting up and leaning forward). A pericardial friction rub may be heard on auscultation.
• Myocarditis: Inflammation of the heart muscle itself can cause chest pain, fatigue, shortness of breath, and palpitations. Myocarditis is often associated with viral infections.
• Mitral Valve Prolapse: While often asymptomatic, mitral valve prolapse can sometimes cause atypical chest pain, palpitations, and fatigue.

6. Vascular Emergencies:

• Aortic Dissection: A tear in the inner lining of the aorta (the main artery from the heart) can cause sudden, severe, tearing or ripping chest pain that may radiate to the back. Aortic dissection is a life-threatening emergency.

Prognosis of Angina: Factors Influencing Outcomes

The prognosis of chronic stable angina, in terms of progression to adverse cardiac events, varies considerably among individuals. Key factors influencing prognosis include the presence of cardiovascular comorbidities (e.g., diabetes, hypertension, heart failure), patient adherence to lifestyle modifications and prescribed medical treatment plans, left ventricular systolic function, exercise tolerance, and the extent and severity of underlying coronary artery disease.

Risk factors associated with a poorer prognosis in angina include diabetes mellitus, prior myocardial infarction, hypertension, advancing age, and male gender. Interestingly, the use of nitrates has also been identified as a negative prognostic indicator for mortality, likely because nitrate use often reflects more advanced and severe coronary artery disease requiring symptom relief.

Complications of Angina: Beyond Chest Pain

Angina, often the initial manifestation of coronary artery disease, carries the significant risk of future cardiac events, most notably myocardial infarction. Studies have estimated that the 10-year risk of MI can exceed 10% in women with chronic stable angina, particularly starting from the time they initiate nitrate therapy for symptom management.

Beyond the potentially fatal complication of MI, chronic stable angina has substantial implications for patients’ quality of life and societal burden. Angina can lead to a reduced quality of life due to limitations in physical activity and daily functioning. Furthermore, it contributes to indirect costs to society through factors such as early retirement, disability, and lost productivity. Therefore, angina management should prioritize not only improving survival and preventing cardiac events but also effectively treating symptoms to enable patients to maintain an active and fulfilling life.

Deterrence and Patient Education: Empowering Patients

Patients with cardiovascular risk factors should be proactively monitored for symptoms of angina. Comprehensive patient education is crucial, emphasizing the importance of recognizing alarming symptoms that warrant immediate medical attention, such as angina occurring at rest or angina that is no longer effectively relieved by nitrates. Risk factor modification is a cornerstone of angina management, and patients should receive thorough education and support regarding dietary changes, regular exercise, and smoking cessation counseling, if applicable. Adherence to prescribed medications is paramount, and patients should be educated about the purpose, proper use, and potential side effects of their medications.

Enhancing Healthcare Team Outcomes: Collaborative Care

Recognizing angina symptoms is the first step in diagnosing coronary artery disease, but the overlapping symptoms with numerous other conditions necessitates a collaborative interprofessional team approach. The healthcare team must be adept at differentiating cardiac from non-cardiac chest pain, recognizing that the quality of pain alone may not be definitive. In specific patient populations, such as individuals with diabetes, angina presentation may be atypical or subtle. A thorough understanding of the patient’s medical history, family history, and risk factors is essential for accurate diagnosis. In the presence of cardiac risk factors, clinicians should maintain a high index of suspicion for a cardiac etiology and proceed with appropriate diagnostic workup.

While cardiologists often lead the management of angina, primary care physicians are frequently at the forefront of initial evaluation, diagnosis, and ongoing management. Effective communication and collaboration between primary care physicians and cardiologists are vital to ensure timely and accurate diagnosis. Missed or delayed diagnosis can have significant consequences, increasing morbidity and mortality.

Cardiology nurses play a critical role in ongoing patient management, monitoring clinical status, assessing treatment adherence, and providing education and support for lifestyle modifications. Pharmacists contribute by optimizing medication regimens, evaluating drug effectiveness, identifying potential drug interactions, and ensuring appropriate medication dosing. Through effective interprofessional collaboration, healthcare teams can optimize outcomes for patients with angina, improving their quality of life and reducing the risk of future adverse cardiac events.

Review Questions

• What are the key components of the differential diagnosis of angina?
• Describe the typical symptoms of stable angina and unstable angina.
• What are the modifiable and non-modifiable risk factors for angina?
• Outline the initial diagnostic evaluation for a patient presenting with chest pain suggestive of angina.
• What are the main treatment strategies for chronic stable angina and unstable angina?

References

1. Balla C, Pavasini R, Ferrari R. Treatment of Angina: Where Are We? Cardiology. 2018;140(1):52-67. PubMed: 29874661
2. Ferrari R, Camici PG, Crea F, Danchin N, Fox K, Maggioni AP, Manolis AJ, Marzilli M, Rosano GMC, Lopez-Sendon JL. Expert consensus document: A ‘diamond’ approach to personalized treatment of angina. Nat Rev Cardiol. 2018 Feb;15(2):120-132. PubMed: 28880025
3. Picard F, Sayah N, Spagnoli V, Adjedj J, Varenne O. Vasospastic angina: A literature review of current evidence. Arch Cardiovasc Dis. 2019 Jan;112(1):44-55. PubMed: 30197243
4. Wolk R, Berger P, Lennon RJ, Brilakis ES, Somers VK. Body mass index: a risk factor for unstable angina and myocardial infarction in patients with angiographically confirmed coronary artery disease. Circulation. 2003 Nov 04;108(18):2206-11. PubMed: 14557360
5. Mancini GB, Gosselin G, Chow B, Kostuk W, Stone J, Yvorchuk KJ, Abramson BL, Cartier R, Huckell V, Tardif JC, Connelly K, Ducas J, Farkouh ME, Gupta M, Juneau M, O’Neill B, Raggi P, Teo K, Verma S, Zimmermann R., Canadian Cardiovascular Society. Canadian Cardiovascular Society guidelines for the diagnosis and management of stable ischemic heart disease. Can J Cardiol. 2014 Aug;30(8):837-49. PubMed: 25064578
6. Wee Y, Burns K, Bett N. Medical management of chronic stable angina. Aust Prescr. 2015 Aug;38(4):131-6. PMC free article: PMC4653970 PubMed: 26648642
7. Boden WE, O’Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, Knudtson M, Dada M, Casperson P, Harris CL, Chaitman BR, Shaw L, Gosselin G, Nawaz S, Title LM, Gau G, Blaustein AS, Booth DC, Bates ER, Spertus JA, Berman DS, Mancini GB, Weintraub WS., COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007 Apr 12;356(15):1503-16. PubMed: 17387127
8. Rayner-Hartley E, Sedlak T. Ranolazine: A Contemporary Review. J Am Heart Assoc. 2016 Mar 15;5(3):e003196. PMC free article: PMC4943285 PubMed: 26979079
9. Silva FM, Pesaro AE, Franken M, Wajngarten M. Acute management of unstable angina and non-ST segment elevation myocardial infarction. Einstein (Sao Paulo). 2015 Jul-Sep;13(3):454-61. PMC free article: PMC4943796 PubMed: 26466065
10. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK., Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001 Aug 16;345(7):494-502. PubMed: 11519503
11. Hjemdahl P, Eriksson SV, Held C, Forslund L, Näsman P, Rehnqvist N. Favourable long term prognosis in stable angina pectoris: an extended follow up of the angina prognosis study in Stockholm (APSIS). Heart. 2006 Feb;92(2):177-82. PMC free article: PMC1860751 PubMed: 15951393
12. Hemingway H, McCallum A, Shipley M, Manderbacka K, Martikainen P, Keskimäki I. Incidence and prognostic implications of stable angina pectoris among women and men. JAMA. 2006 Mar 22;295(12):1404-11. PubMed: 16551712
13. Kloner RA, Chaitman B. Angina and Its Management. J Cardiovasc Pharmacol Ther. 2017 May;22(3):199-209. PubMed: 28196437